Other News To Note
Tuesday, October 25, 2011
PolyMedix Inc., of Radnor, Pa., presented clinical and preclinical data that showed its defensin-mimetic antibiotic, PMX-30063, may be active against Gram-positive and certain evaluated Gram-negative organisms, including multidrug-resistant species. In a Phase I trial, PMX-30063 also demonstrated antimicrobial activity in human blood plasma against both resistant and susceptible strains of Staphylococcus aureus.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.